Stoked Bio operates a biotechnology platform that utilizes artificial intelligence for molecular property prediction and design, focusing on the development of therapeutics for resistant bacterial, fungal, and cancer indications. The company addresses the challenge of unmet clinical needs by enabling rapid and cost-effective drug discovery through data-driven refinement of drug candidates.
Funding
Funding not disclosed
Founders
Product
Problem
The development of new therapeutics for resistant bacterial, fungal, and cancer indications is slow and costly, resulting in unmet clinical needs. Traditional drug discovery methods often struggle to efficiently identify and refine promising drug candidates.
Solution
Stoked Bio offers a biotechnology platform that leverages artificial intelligence (AI) for molecular property prediction and design to accelerate the drug discovery process. The platform interactively refines novel, therapeutically relevant scaffolds, enabling the design of improved drug candidates. By using data-driven approaches, Stoked Bio aims to reduce the time and cost associated with developing new drugs for underserved diseases. The company focuses on advancing development candidates against resistant bacterial, fungal, and cancer indications.
Target Audience
The primary target audience includes pharmaceutical companies, research institutions, and healthcare organizations focused on developing novel therapeutics for resistant bacterial, fungal, and cancer indications.
Features
- AI-driven molecular property prediction for identifying new treatment options
- Interactive refinement of drug candidates using AI to optimize therapeutic potential
- Development of novel therapeutics for resistant bacterial infections
- Development of novel therapeutics for fungal infections
- Development of novel therapeutics for cancer indications